Beryl Drugs Ltd
Beryl Drugs Ltd is principally engaged in Manufacturing of Bulk Drugs. It was incorporated in 1993.[1]
- Market Cap ₹ 17.6 Cr.
- Current Price ₹ 34.7
- High / Low ₹ 45.0 / 13.1
- Stock P/E 15.0
- Book Value ₹ 17.8
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 10.0 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company's working capital requirements have reduced from 110 days to 71.3 days
Cons
- Promoter holding is low: 26.4%
- Company has a low return on equity of 0.04% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9.16 | 14.42 | 14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 30.02 | |
8.68 | 13.50 | 13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 27.11 | |
Operating Profit | 0.48 | 0.92 | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.91 |
OPM % | 5.24% | 6.38% | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 9.69% |
0.09 | 0.12 | 0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.00 | |
Interest | 0.16 | 0.14 | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.39 |
Depreciation | 0.28 | 0.29 | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.03 |
Profit before tax | 0.13 | 0.61 | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.49 |
Tax % | 30.77% | 36.07% | 37.21% | 38.46% | 32.00% | -18.92% | 22.05% | 26.25% | 68.75% | 31.43% | 30.53% | 22.22% | |
0.09 | 0.39 | 0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 1.17 | |
EPS in Rs | 0.18 | 0.76 | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 2.31 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 12% |
3 Years: | 28% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 4% |
3 Years: | 149% |
TTM: | 409% |
Stock Price CAGR | |
---|---|
10 Years: | 1% |
5 Years: | 37% |
3 Years: | 81% |
1 Year: | 153% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 2% |
3 Years: | 0% |
Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.06 | 5.06 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
Reserves | 0.67 | 1.06 | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.92 |
0.89 | 0.89 | 1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 4.96 | |
1.89 | 1.92 | 1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 5.31 | |
Total Liabilities | 8.51 | 8.93 | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 19.28 |
2.33 | 2.85 | 2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.22 | |
CWIP | 0.43 | 0.00 | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.92 | 1.24 | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.30 |
4.83 | 4.84 | 6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 12.76 | |
Total Assets | 8.51 | 8.93 | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 19.28 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.77 | 0.78 | 0.00 | 0.70 | -0.13 | 0.37 | -0.10 | 3.35 | 0.18 | 0.34 | -0.29 | 2.48 | |
-0.70 | -0.70 | 0.00 | 0.02 | 0.17 | 0.32 | -0.03 | -5.01 | -1.55 | 0.26 | 0.54 | -1.30 | |
0.02 | 0.08 | 0.00 | -0.09 | -0.23 | -0.19 | -0.36 | 1.62 | 1.67 | -0.54 | -0.43 | -1.17 | |
Net Cash Flow | 0.09 | 0.16 | 0.00 | 0.63 | -0.19 | 0.50 | -0.49 | -0.04 | 0.30 | 0.06 | -0.18 | 0.01 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 94.04 | 56.70 | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 |
Inventory Days | 72.89 | 30.75 | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | |
Days Payable | 94.59 | 52.72 | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | |
Cash Conversion Cycle | 72.34 | 34.73 | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 |
Working Capital Days | 80.09 | 35.69 | 75.56 | 84.70 | 105.37 | 120.89 | 105.53 | 43.59 | 82.25 | 120.45 | 138.39 | 71.26 |
ROCE % | 4.36% | 11.59% | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% |
Documents
Announcements
- Board Meeting Outcome for OUTCOME OF BOARD MEETING 20 Apr
- COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED 31.03.2024 17 Apr
- Declaration As Per Circular SEBI/HO/DDHS/CIR/P/2018/144 Dated 26.11.2018, Regarding Large Entity Or Large Corporate. 13 Apr
- Compliances-Reg.24(A)-Annual Secretarial Compliance 13 Apr
- Board Meeting Intimation for To Take Note Of General Disclosures Of Interest Of Directors Under Section 184 (1) In Form MBP-1 For The Year Ended 2024-2025 12 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Offerings
The company offers a broad range of manufacturing options to clients such as small volume injectables in liquid and dry power form, variety of eye and ear drops, IV Fluids in polypack and glass bottles and variety of veterinary medicines.[1]